Core Therapeutic Areas
To strengthen our scientific core, we are investing in areas where we see the greatest opportunity and where we believe we can deliver the best value. We also forge novel partnerships that allow us to access the best science.
While we continue to pursue and invest in additional therapies in early and late stages of clinical development (see Worldwide Research & Development (WRD)  and Biopharmaceuticals  pages), the following are Pfizer's priority R&D therapeutic areas:
NOTE: For opportunities that fall into the pre-clinical proof of concept space, generally before phase 2b of development, visit the WRD links below. For post-clinical proof of concept, generally post phase 2a of development, visit the biopharmaceutical business units.
Cardiovascular and Metabolic Disease
Pain and Sensory